|
US6080216A
(en)
*
|
1998-04-22 |
2000-06-27 |
3M Innovative Properties Company |
Layered alumina-based abrasive grit, abrasive products, and methods
|
|
WO2005049622A1
(ja)
*
|
2003-11-19 |
2005-06-02 |
Japan Tobacco Inc. |
5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
|
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
|
US7795247B2
(en)
*
|
2004-10-26 |
2010-09-14 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
|
RU2007119562A
(ru)
*
|
2004-10-26 |
2008-12-10 |
Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) |
Тетрациклические производные индолов в качестве противовирусных агентов
|
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
US8278322B2
(en)
|
2005-08-01 |
2012-10-02 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
GB0518390D0
(en)
*
|
2005-09-09 |
2005-10-19 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US7399758B2
(en)
*
|
2005-09-12 |
2008-07-15 |
Meanwell Nicholas A |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7473688B2
(en)
*
|
2005-09-13 |
2009-01-06 |
Bristol-Myers Squibb Company |
Indolobenzazepine HCV NS5B inhibitors
|
|
WO2007092000A1
(en)
*
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
|
US7456165B2
(en)
*
|
2006-02-08 |
2008-11-25 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
|
GB0608928D0
(en)
*
|
2006-05-08 |
2006-06-14 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
CN101443336B
(zh)
*
|
2006-05-17 |
2012-07-04 |
百时美施贵宝公司 |
环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
|
|
US7456166B2
(en)
*
|
2006-05-17 |
2008-11-25 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7521443B2
(en)
*
|
2006-05-17 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7521441B2
(en)
*
|
2006-05-22 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
WO2007140200A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
|
DE602007006796D1
(de)
*
|
2006-05-25 |
2010-07-08 |
Bristol Myers Squibb Co |
Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
|
|
US7452876B2
(en)
*
|
2006-06-08 |
2008-11-18 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
ES2448494T3
(es)
|
2006-07-13 |
2014-03-14 |
Achillion Pharmaceuticals, Inc. |
Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral
|
|
PE20081113A1
(es)
*
|
2006-07-20 |
2008-10-03 |
Genelabs Tech Inc |
Inhibidores virales policiclicos
|
|
CN101583372A
(zh)
|
2006-10-24 |
2009-11-18 |
默克公司 |
Hcv ns3蛋白酶抑制剂
|
|
US8138164B2
(en)
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
CA2667165A1
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
JP5268927B2
(ja)
|
2006-10-27 |
2013-08-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvns3プロテアーゼ阻害剤
|
|
WO2008057208A2
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US8101595B2
(en)
|
2006-12-20 |
2012-01-24 |
Istituto di Ricerche di Biologia Molecolare P. Angletti SpA |
Antiviral indoles
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
JP5055377B2
(ja)
|
2006-12-22 |
2012-10-24 |
シェーリング コーポレイション |
[5,6−環]環形成インドール誘導体およびその使用方法
|
|
KR20090106539A
(ko)
|
2006-12-22 |
2009-10-09 |
쉐링 코포레이션 |
Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
|
|
JP5079818B2
(ja)
*
|
2006-12-22 |
2012-11-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvおよび関連するウイルス疾患の治療または予防のための4,5−環インドール誘導体
|
|
US7541351B2
(en)
*
|
2007-01-11 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7541352B2
(en)
*
|
2007-02-02 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7517872B2
(en)
|
2007-02-22 |
2009-04-14 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
EP2125113A2
(en)
*
|
2007-02-26 |
2009-12-02 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of hcv replication
|
|
WO2008106166A2
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
|
|
US7998951B2
(en)
*
|
2007-03-05 |
2011-08-16 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
|
CN101679437B
(zh)
*
|
2007-03-13 |
2013-04-17 |
百时美施贵宝公司 |
环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
|
|
US7521444B2
(en)
*
|
2007-03-14 |
2009-04-21 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7541353B2
(en)
*
|
2007-03-14 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7547690B2
(en)
*
|
2007-03-14 |
2009-06-16 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US7538102B2
(en)
*
|
2007-03-14 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US7538103B2
(en)
*
|
2007-03-15 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
MX2009011930A
(es)
|
2007-05-04 |
2009-11-18 |
Vertex Pharma |
Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
|
|
AU2008277442A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
|
CN101754974B
(zh)
|
2007-07-19 |
2016-02-03 |
Msd意大利有限公司 |
作为抗病毒剂的大环化合物
|
|
US7652004B2
(en)
*
|
2007-08-09 |
2010-01-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7642251B2
(en)
*
|
2007-08-09 |
2010-01-05 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8143243B2
(en)
*
|
2007-08-09 |
2012-03-27 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
RU2010111550A
(ru)
|
2007-08-29 |
2011-10-10 |
Шеринг Корпорейшн (US) |
2,3-замещенные индольные производные для лечения вирусных инфекций
|
|
JP5179585B2
(ja)
*
|
2007-08-29 |
2013-04-10 |
メルク・シャープ・アンド・ドーム・コーポレーション |
四環系インドール誘導体およびその使用法
|
|
WO2009032124A1
(en)
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
Substituted indole derivatives and methods of use thereof
|
|
EP2195317B1
(en)
|
2007-08-29 |
2012-01-18 |
Schering Corporation |
2,3-substituted azaindole derivatives for treating viral infections
|
|
CN102317285A
(zh)
|
2007-11-16 |
2012-01-11 |
先灵公司 |
3-氨基磺酰基取代的吲哚衍生物及其使用方法
|
|
US8765757B2
(en)
|
2007-11-16 |
2014-07-01 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
US8124601B2
(en)
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US8129367B2
(en)
*
|
2007-11-21 |
2012-03-06 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
EP2234977A4
(en)
|
2007-12-19 |
2011-04-13 |
Boehringer Ingelheim Int |
VIRAL POLYMERASE INHIBITORS
|
|
CN101910177B
(zh)
|
2007-12-24 |
2013-08-28 |
泰博特克药品公司 |
作为丙型肝炎病毒抑制剂的大环吲哚
|
|
US8147818B2
(en)
*
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
KR20100126560A
(ko)
*
|
2008-03-27 |
2010-12-01 |
브리스톨-마이어스 스큅 컴퍼니 |
피롤리딘 융합된 인돌로벤자디아제핀 hcv ns5b 억제제
|
|
US8178523B2
(en)
*
|
2008-03-27 |
2012-05-15 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
ATE531373T1
(de)
*
|
2008-03-27 |
2011-11-15 |
Bristol Myers Squibb Co |
Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
|
|
US8138171B2
(en)
*
|
2008-03-27 |
2012-03-20 |
Bristol-Myers Squibb Company |
Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
|
|
CN102014911A
(zh)
|
2008-04-28 |
2011-04-13 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
|
US8133884B2
(en)
*
|
2008-05-06 |
2012-03-13 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
JP5580814B2
(ja)
|
2008-06-13 |
2014-08-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3環式インドール誘導体およびその使用方法
|
|
TWI454476B
(zh)
*
|
2008-07-08 |
2014-10-01 |
Tibotec Pharm Ltd |
用作c型肝炎病毒抑制劑之巨環吲哚衍生物
|
|
ES2392611T3
(es)
|
2008-07-22 |
2012-12-12 |
Merck Sharp & Dohme Corp. |
Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
|
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
|
CN102176911B
(zh)
|
2008-08-11 |
2014-12-10 |
葛兰素史密丝克莱恩有限责任公司 |
新的腺嘌呤衍生物
|
|
BRPI0917458A2
(pt)
|
2008-08-11 |
2015-12-01 |
Glaxosmithkline Llc |
composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
|
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
|
ES2527166T3
(es)
*
|
2008-12-10 |
2015-01-21 |
Achillion Pharmaceuticals, Inc. |
Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral
|
|
US20100152103A1
(en)
*
|
2008-12-10 |
2010-06-17 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
|
|
KR20110094352A
(ko)
*
|
2008-12-22 |
2011-08-23 |
에프. 호프만-라 로슈 아게 |
헤테로사이클릭 항바이러스 화합물
|
|
MX2011006890A
(es)
|
2008-12-23 |
2011-07-20 |
Pharmasset Inc |
Analogos de nucleosidos.
|
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
|
KR20110116136A
(ko)
|
2009-01-07 |
2011-10-25 |
싸이넥시스, 인크. |
Hcv 및 hiv 감염의 치료에 사용하기 위한 사이클로스포린 유도체
|
|
EP2396329B1
(en)
*
|
2009-02-11 |
2014-10-29 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis c
|
|
US8143244B2
(en)
*
|
2009-02-26 |
2012-03-27 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US20190127365A1
(en)
|
2017-11-01 |
2019-05-02 |
Merck Sharp & Dohme Corp. |
Inhibitors of hepatitis c virus replication
|
|
HUE027755T2
(en)
|
2009-03-27 |
2016-11-28 |
Merck Sharp & Dohme |
Inhibitors of hepatitis C virus replication
|
|
AU2010232729A1
(en)
*
|
2009-03-31 |
2011-10-20 |
Arqule, Inc. |
Substituted indolo-pyridinone compounds
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
|
RS53745B1
(sr)
|
2010-02-10 |
2015-06-30 |
Glaxosmithkline Llc |
6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat
|
|
US8575340B2
(en)
|
2010-02-10 |
2013-11-05 |
Glaxosmithkline Llc |
Purine derivatives and their pharmaceutical uses
|
|
MA34147B1
(fr)
*
|
2010-03-09 |
2013-04-03 |
Merck Sharp & Dohme |
Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
|
|
TW201136945A
(en)
|
2010-03-31 |
2011-11-01 |
Pharmasset Inc |
Purine nucleoside phosphoramidate
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
AP2012006535A0
(en)
|
2010-03-31 |
2012-10-31 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorous containing actives
|
|
EP2585438B1
(en)
|
2010-06-24 |
2014-08-20 |
Janssen R&D Ireland |
PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
|
|
EP2621279B1
(en)
*
|
2010-09-29 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
|
CN103534256B
(zh)
|
2010-12-30 |
2016-08-10 |
益安药业 |
大环丙型肝炎丝氨酸蛋白酶抑制剂
|
|
KR20140003521A
(ko)
|
2010-12-30 |
2014-01-09 |
이난타 파마슈티칼스, 인코포레이티드 |
페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
|
|
WO2012122716A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
|
HRP20180237T4
(hr)
|
2011-09-16 |
2020-12-11 |
Gilead Pharmasset Llc |
Metode za liječenje hcv-a
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
CN104023726A
(zh)
|
2011-10-21 |
2014-09-03 |
艾伯维公司 |
用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
|
|
DE112012003510T5
(de)
|
2011-10-21 |
2015-03-19 |
Abbvie Inc. |
Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
EP3091022A3
(en)
*
|
2012-07-18 |
2016-12-14 |
Bristol-Myers Squibb Holdings Ireland |
Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
|
|
WO2014110687A1
(en)
|
2013-01-16 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
|
|
EP2950786B1
(en)
|
2013-01-31 |
2019-11-27 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2014121418A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121416A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014145507A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
|
WO2014145600A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
|
|
AU2014227849A1
(en)
|
2013-03-15 |
2015-10-01 |
Achillion Pharmaceuticals, Inc. |
Sovaprevir polymorphs and methods of manufacture thereof
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
WO2015061407A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
|
KR20160124157A
(ko)
|
2014-02-20 |
2016-10-26 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
|
|
ES2917887T3
(es)
|
2014-11-13 |
2022-07-12 |
Glaxosmithkline Biologicals Sa |
Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
|
|
JP6411676B2
(ja)
|
2015-12-03 |
2018-10-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Stingの調節因子としての環状プリンジヌクレオチド
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
SG10201900628RA
(en)
|
2016-04-07 |
2019-02-27 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
JP7129703B2
(ja)
|
2016-04-28 |
2022-09-02 |
エモリー ユニバーシティー |
アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
|
|
CN110769830A
(zh)
|
2017-05-12 |
2020-02-07 |
马瓦隆治疗有限公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
US20220251079A1
(en)
|
2019-05-16 |
2022-08-11 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021119753A1
(en)
|
2019-12-18 |
2021-06-24 |
Ctxt Pty Limited |
Compounds
|
|
US12274700B1
(en)
|
2020-10-30 |
2025-04-15 |
Accencio LLC |
Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
|